Literature DB >> 971701

Observations on the efficacy and pharmacokinetics of sotalol after oral administration.

H C Brown, S G Carruthers, J G Kelly, D G McDevitt, R G Shanks.   

Abstract

The effects of sotalol after oral administration were measured on the tachycardia induced by strenuous exercise in normal subjects. Plasma sotalol levels were also determined. The oral administration of sotalol (50, 100, 200 and 400 mg) to 6 subjects produced a progressive reduction in the tachycardia induced by severe exercise. This was similar to the effects of 25, 50, 100, 200, 400 and 800 mg given to different subjects. Each increase in sotalol dose produced a successively greater reduction in exercise tachycardia. This did not appear to be maximum even with 800 mg. Oral sotalol was rapidly absorbed and produced peak blood levels in 2 - 3 hours. The plasma levels of sotalol measured 2 hours after the oral administration of 25 to 800 mg showed never more than a six-fold variation between different subject. The half-life of sotalol in plasma was 12.7 +/- SE 1.6 hours. There was a significant correlation between the logarithm of the plasma sotalol concentration and the percentage reduction of exercise heart rate. It is concluded that the oral administration of sotalol either once or twice daily (depending on dose level) will provide satisfactory 24-hour blockade of beta-adrenoceptors.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 971701     DOI: 10.1007/BF00606550

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  16 in total

1.  Pharmacological and toxicological properties of two new beta-adrenergic receptor antagonists.

Authors:  P M Lish; J H Weikel; K W Dungan
Journal:  J Pharmacol Exp Ther       Date:  1965-08       Impact factor: 4.030

2.  Cardiovascular pharmacology of two new beta-adrenergic receptor antagonists.

Authors:  H C Stanton; T Kirchgessner; K Parmenter
Journal:  J Pharmacol Exp Ther       Date:  1965-08       Impact factor: 4.030

3.  Pharmacokinetic studies of practolol, a beta adrenergic antagonist, in man.

Authors:  G Bodem; C A Chidsey
Journal:  Clin Pharmacol Ther       Date:  1973 Jan-Feb       Impact factor: 6.875

4.  Potentiation of bronchomotor responses by beta adrenergic antagonists.

Authors:  L Diamond
Journal:  J Pharmacol Exp Ther       Date:  1972-06       Impact factor: 4.030

5.  Blood levels of practolol after oral and parenteral administration and their relationship to exercise heart rate.

Authors:  S G Carruthers; J G Kelly; D G McDevitt; R G Shanks
Journal:  Clin Pharmacol Ther       Date:  1974-05       Impact factor: 6.875

6.  Inhibition of cardiac chronotropic action of isoproterenol by Sotalol (MJ 1999) in rat, dog and man.

Authors:  P M Lish; M V Shelanski; J A LaBudde; W R Williams
Journal:  Curr Ther Res Clin Exp       Date:  1967-06

7.  Effects of sotalol and propranolol administered orally in man.

Authors:  N Svedmyr; B Jakobsson; R Malmberg
Journal:  Eur J Pharmacol       Date:  1969-10       Impact factor: 4.432

8.  Plasma propranolol levels in adults with observations in four children.

Authors:  D G Shand; E M Nuckolls; J A Oates
Journal:  Clin Pharmacol Ther       Date:  1970 Jan-Feb       Impact factor: 6.875

9.  Pharmacokinetics of the -adrenergic blocker sotalol in dogs.

Authors:  K Schnelle; E R Garrett
Journal:  J Pharm Sci       Date:  1973-03       Impact factor: 3.534

Review 10.  Pharmacokinetic properties of the beta-adrenergic receptor blocking drugs.

Authors:  D G Shand
Journal:  Drugs       Date:  1974       Impact factor: 9.546

View more
  24 in total

Review 1.  Therapeutic drug monitoring of antiarrhythmic drugs.

Authors:  Gesche Jürgens; Niels A Graudal; Jens P Kampmann
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

2.  Absorption kinetics of oral sotalol combined with cisapride and sublingual sotalol in healthy subjects.

Authors:  V H Deneer; L Lie-A-Huen; J H Kingma; J H Proost; J C Kelder; J R Brouwers
Journal:  Br J Clin Pharmacol       Date:  1998-05       Impact factor: 4.335

Review 3.  The assessment of beta-adrenoceptor blocking drugs in man.

Authors:  D G McDevitt
Journal:  Br J Clin Pharmacol       Date:  1977-08       Impact factor: 4.335

4.  Evaluation of once daily sotalol administration in man.

Authors:  D G McDewitt; R G Shanks
Journal:  Br J Clin Pharmacol       Date:  1977-04       Impact factor: 4.335

Review 5.  Approach to Management of Premature Ventricular Contractions.

Authors:  Michael P O'Quinn; Anthony J Mazzella; Prabhat Kumar
Journal:  Curr Treat Options Cardiovasc Med       Date:  2019-09-05

6.  Torsade de pointes induced by sotalol despite therapeutic plasma sotalol concentrations.

Authors:  R Krapf; M Gertsch
Journal:  Br Med J (Clin Res Ed)       Date:  1985-06-15

7.  Once daily beta-adrenoceptor blockade in hypertension: an ambulatory assessment.

Authors:  S Mann; M W Craig; V Balasubramanian; E B Raftery
Journal:  Br J Clin Pharmacol       Date:  1981-08       Impact factor: 4.335

8.  Observation on the efficacy and pharmacokinetics of betaxolol (SL 75212), a cardioselective beta-adrenoceptor blocking drug.

Authors:  K Balnave; J D Neill; C J Russell; D W Harron; W J Leahey; R Wilson; R G Shanks
Journal:  Br J Clin Pharmacol       Date:  1981-02       Impact factor: 4.335

9.  Comparative pharmacological and pharmacokinetic observations on propranolol (long acting formulation) and bendrofluazide administered separately and concurrently to volunteers.

Authors:  D P Nicholls; D W Harron; J McAinsh; W M Castle; N P Barker; R G Shanks
Journal:  Br J Clin Pharmacol       Date:  1982-11       Impact factor: 4.335

10.  Comparison of once and twice daily administration of sotalol in the treatment of hypertension.

Authors:  I Parvinen; E Paukkala
Journal:  Eur J Clin Pharmacol       Date:  1979-06-12       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.